565 related articles for article (PubMed ID: 20635906)
1. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
Peinert S; Kershaw MH; Prince HM
Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
[No Abstract] [Full Text] [Related]
2. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.
Hombach AA; Abken H
Immunotherapy; 2013 Jul; 5(7):677-81. PubMed ID: 23829616
[No Abstract] [Full Text] [Related]
3. Bispecific antibodies and diabodies for cancer immunotherapy.
Elsässer-Beile U; Bühler P
Immunotherapy; 2012 May; 4(5):459-60. PubMed ID: 22642325
[No Abstract] [Full Text] [Related]
4. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
Chmielewski M; Hombach AA; Abken H
Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680
[TBL] [Abstract][Full Text] [Related]
5. Armed T cells with CAR for cancer immunotherapy.
Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
[No Abstract] [Full Text] [Related]
6. Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.
Davies DM; Maher J
Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):165-78. PubMed ID: 20373147
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
9. Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins.
Klesmith JR; Su L; Wu L; Schrack IA; Dufort FJ; Birt A; Ambrose C; Hackel BJ; Lobb RR; Rennert PD
Mol Pharm; 2019 Aug; 16(8):3544-3558. PubMed ID: 31242389
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.
Chicaybam L; Sodré AL; Bonamino M
Int Rev Immunol; 2011; 30(5-6):294-311. PubMed ID: 22053970
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with T cells bearing chimeric antitumor receptors.
Paillard F
Hum Gene Ther; 1999 Jan; 10(2):151-3. PubMed ID: 10022540
[No Abstract] [Full Text] [Related]
12. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
13. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
14. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Shirasu N; Kuroki M
Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
[TBL] [Abstract][Full Text] [Related]
15. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes.
Baxevanis CN; Papamichail M
Cancer Immunol Immunother; 2004 Oct; 53(10):893-903. PubMed ID: 15168086
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
Luo C; Wei J; Han W
Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
[TBL] [Abstract][Full Text] [Related]
18. CART trials are going ahead.
Wei J; Han W
Sci China Life Sci; 2017 Nov; 60(11):1276-1279. PubMed ID: 29170890
[No Abstract] [Full Text] [Related]
19. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.
You F; Jiang L; Zhang B; Lu Q; Zhou Q; Liao X; Wu H; Du K; Zhu Y; Meng H; Gong Z; Zong Y; Huang L; Lu M; Tang J; Li Y; Zhai X; Wang X; Ye S; Chen D; Yuan L; Qi L; Yang L
Sci China Life Sci; 2016 Apr; 59(4):386-97. PubMed ID: 26961900
[TBL] [Abstract][Full Text] [Related]
20. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
Holzinger A; Abken H
Cancer Immunol Immunother; 2017 Nov; 66(11):1505-1507. PubMed ID: 28755091
[No Abstract] [Full Text] [Related]
[Next] [New Search]
